The 44th J.P. Morgan Healthcare Conference (JPM 2026), the world's premier healthcare partnership and investment forum, will convene in San Francisco from January 12 to 15, 2026. Beijing Sungen Biomedical Technology Co., Ltd. (Sungen), a subsidiary of Beijing Hotgen Biotech Co., Ltd. is poised to participate actively at this global event. Dedicated to deep innovation in therapeutic antibodies, Sungen will showcase a portfolio of world-class First-in-Class (FIC) antibody therapeutics, marking the beginning of a new chapter in global collaboration.
At the conference, Sungen will present breakthrough advancements across its innovative drug pipelines. With a strategic focus on high-clinical-need areas such as cardiovascular diseases and tumors, the company has advanced multiple antibody drug candidates with global-level FIC potential into the global development forefront.
We look forward to engaging in in-depth discussions with global industry peers, leading research institutions, and investors during the event. Together, we aim to address critical unmet medical needs worldwide, drive profound innovation in antibody therapeutics, and deliver more transformative FIC drugs to global patients.
Updated: Jan 06, 2026
